8-K

a5916885.htm

PFIZER INC. 8-K

a5916885.htm

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES

EXCHANGE ACT OF 1934

Date of

report (Date of earliest event reported): March 13, 2009

PFIZER

INC.

(Exact

name of registrant as specified in its charter)

Delaware

1-3619

13-5315170

(State

or other

(Commission

File

(I.R.S.

Employer

jurisdiction

of

(Number)

Identification

No.)

incorporation)

235

East 42nd Street

10017

New

York, New York

(Zip

Code)

(Address

of principal executive offices)

Registrant's

telephone number, including area code:

(212)

573-2323

Not

Applicable

(Former

Name or Former Address, if changed since last report)

Check the

appropriate box below if the Form 8-K filing is intended to simultaneously

satisfy the obligation of the registrant under any of the following provisions

(see General Instruction A.2. below):

[x]

Written communication pursuant to Rule 425 under the Securities Act (17 CFR

230.425)

[ ]

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR

240.14a-12)

[ ]

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

(17 CFR 240.14d-2 (b))

[ ]

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

(17 CFR 240.13e-4(c))

Item

8.01 Other Events

As previously announced, Pfizer Inc., a Delaware corporation (the Company ), Wagner Acquisition Corp., a Delaware corporation and direct wholly-owned subsidiary of the Company ( Merger Sub ), and Wyeth, a

Delaware corporation, entered into a

definitive Agreement and Plan of Merger dated as of January 25, 2009 (the Merger

Agreement ). Pursuant to

the Merger Agreement and subject to the conditions set forth therein,

Merger Sub will merge with and into

Wyeth,

with Wyeth surviving as a wholly-owned

subsidiary of the Company (the Merger ).

The Merger is subject to Wyeth shareholder approval,

governmental and regulatory approvals, the satisfaction of certain conditions

related to the debt financing for the transaction, and other usual and customary

closing conditions.

The

preliminary unaudited pro forma condensed combined financial information

reflecting the Merger and Wyeth s audited historical consolidated financial

statements and related notes are attached hereto as Exhibits 99.1 and

99.2.

Forward Looking Statements

This Current Report on Form 8-K (including information

included or incorporated by reference herein) includes "forward-looking

statements" within the meaning of the safe harbor provisions of the United

States Private Securities Litigation Reform Act of 1995. Such statements may

include, but are not limited to, statements about the benefits of the proposed

merger between Pfizer and Wyeth, including future financial and operating

results, the combined company's plans, objectives, expectations and intentions

and other statements that are not historical facts. Such statements are based

upon the current beliefs and expectations of Pfizer's and Wyeth's management and

are subject to significant risks and uncertainties. Actual results may differ

from those set forth in the forward-looking statements. Neither Pfizer nor Wyeth

undertake any obligation to update publicly or revise any forward-looking

statements. The following factors, among others, could cause actual

results to differ from those set forth in the forward-looking statements: the

possibility that the expected synergies from the proposed merger of Pfizer and

Wyeth will not be realized, or will not be realized within the expected time

period, due to, among other things, the impact of pharmaceutical industry

regulation and pending legislation that could affect the pharmaceutical

industry; the ability to obtain governmental and self-regulatory organization

approvals of the merger on the proposed terms and schedule; the failure of Wyeth

stockholders to approve the merger; the risk that the businesses will not be

integrated successfully; disruption from the merger making it more difficult to

maintain business and operational relationships; the possibility that the merger

does not close, including, but not limited to, due to the failure to satisfy the

closing conditions; Pfizer's and Wyeth's ability to accurately predict future

market conditions; dependence on the effectiveness of Pfizer's and Wyeth's

patents and other protections for innovative products; the risk of new and

changing regulation and health policies in the U.S. and internationally and the

exposure to litigation and/or regulatory actions. Additional factors that could

cause results to differ materially from those described in the forward-looking

statements can be found in Pfizer's 2008 Annual Report on Form 10-K filed with

the Securities and Exchange Commission (the "SEC") on February 27, 2009, Wyeth's

2008 Annual Report on Form 10-K filed with the SEC on February 27, 2009,

included in the Risk Factors section of each of these filings,

and each company's other filings with the SEC available at the SEC's Internet

site (http://www.sec.gov).

Additional

Information

In

connection with the proposed Merger, the Company will file with the SEC a

Registration Statement on Form S-4 that will include a proxy statement of Wyeth

that also constitutes a prospectus of the Company. Wyeth will mail

the proxy statement/prospectus to its stockholders. The Company and

Wyeth urge investors and security holders to read the proxy statement/prospectus

regarding the proposed Merger when it becomes available because it will contain

important information. You may obtain copies of all documents filed

with the SEC regarding this transaction, free of charge, at the SEC s website

(www.sec.gov). You

may also obtain these documents, free of charge, from the Company s website,

www.pfizer.com,

under the tab Investors and then under the tab SEC Filings . You

may also obtain these documents, free of charge, from Wyeth s website, www.wyeth.com, under

the heading Investor Relations and then under the tab Financial Reports/SEC

Filings . The Company, Wyeth and their respective directors,

executive officers and certain other members of management and employees may be

soliciting proxies from Wyeth stockholders in favor of the

Merger. Information regarding the persons who may, under the rules of

the SEC, be deemed participants in the solicitation of the Wyeth stockholders in

connection with the proposed Merger will be set forth in the proxy

statement/prospectus when it is filed with the SEC. You can find

information about the Company s executive officers and directors in its

definitive proxy statement filed with the SEC on March 13, 2009. You

can find information about Wyeth s executive officers and directors in its

definitive proxy statement filed with the SEC on March 14, 2008. You

can obtain free copies of these documents from the Company and Wyeth using the

contact information above.

Item

9.01 Financial Statements and Exhibits

(d)

Exhibits

23.1

Consent

of PricewaterhouseCoopers LLP, Independent Registered Public Accounting

Firm of Wyeth

99.1

Wyeth s

Audited Historical Consolidated Financial Statements and Related

Notes

99.2

Pfizer s

preliminary Unaudited Pro Forma Condensed Combined Financial Statements

and Related

Notes

SIGNATURE

Under the

requirements of the Securities Exchange Act of 1934, the registrant has caused

this report to be signed on its behalf by the authorized

undersigned.

PFIZER

INC.

By:/s/ Matthew

Lepore

Matthew

Lepore

Vice

President, Chief Counsel Corporate Governance,

and

Assistant General

Counsel

Dated:

March 13, 2009

EXHIBIT

INDEX

Exhibit No.

Description

23.1

Consent

of PricewaterhouseCoopers LLP, Independent Registered Public Accounting

Firm of Wyeth

99.1

Wyeth s

Audited Historical Consolidated Financial Statements

99.2

Pfizer s

preliminary Unaudited Pro Forma Condensed Combined Financial

Statements